Exploring the potential of circulating tumour DNA to monitor treatment response in salivary duct carcinoma patients of the CABO-ASAP trial
- PMID: 37939426
- DOI: 10.1016/j.oraloncology.2023.106620
Exploring the potential of circulating tumour DNA to monitor treatment response in salivary duct carcinoma patients of the CABO-ASAP trial
Keywords: Cabozantinib; Circulating tumour DNA; Head and Neck neoplasms [MeSH]; Salivary duct carcinoma; Salivary gland neoplasms [MeSH].
Conflict of interest statement
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [JS: Speaker’s honorarium: ‘Astellas, Bayer’. ML: Advisory (institution): AstraZeneca, GlaxoSmithKline, Illumina, Janssen-Cilag, Lilly, MSD, Medtalks. CvH: Advisory (institution): Bayer, Bristol-Myers Squibb, Ipsen, MSD, Regeneron, and Philips Molecular Pathway Diagnostics. Research grant (institution): Astra Zeneca, Bristol-Myers Squibb, MSD, Merck, Ipsen, Novartis, and Sanofi.JW, TdB, GV, WvB, MU, AvEvG, CD: Nothing to declare.].
References
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical
